Previous 10 | Next 10 |
home / stock / lexxw / lexxw news
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs for 2022. According to the update, the studies mentioned in the announcement represent only a fraction of ...
KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for several new and ongoing DehydraTECH TM applied R&D programs for 2022. The studies ment...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition, the company provided updates on three ongoing human clinical studies evaluating its proprietary Dehydra...
DehydraTECH-CBD also being evaluated in three other human clinical studies Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...
(TheNewswire) - New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECH TM -CBD for reducing seizure activity Kelowna, British Columbia - TheNewswire - November 1, 2021 - Lexaria Bioscienc...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its recent oral tetrahydrocannabinol (“THC”) absorption study THC-A21-1 revealed that DehydraTECH(TM)-THC delivered via oral ingestion required only 15 minutes to del...
--News Direct-- DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes Kelowna, British Columbia – TheNewswire - October 13, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Co...
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, was featured in the latest episode of the “ Stock2Me Podcast ,” an IBN (InvestorBrandNetwork) solution to provide specialized content distribution via widespread syndication chann...
--News Direct-- - DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls - Peak levels achieved were up to 10x higher than controls Kelowna, British Columbia - TheNewswire – October 5, 2021 – Lexaria Bioscie...
(TheNewswire) Vancouver, British Columbia – TheNewswire - September 21, 2021. Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (the “ Company ” or “Lexston” ) is pleased to announce the acquisi...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Warrant Website:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects ...